Aktienanalyse zu Anika Therapeutics Inc (ANIK)ANIKAnika Therapeutics Inc

Anika Therapeutics, Inc. is engaged in the osteoarthritis pain management and regenerative solutions space focused on early intervention orthopedics. The Company is leveraging its core expertise in hyaluronic acid and implant solutions. It partners with clinicians to provide minimally invasive products that restore active living for people around the world. It is developing, manufacturing and commercializing products on its hyaluronic acid (HA) technology platform. It is focused on spaces within orthopedics, including osteoarthritis pain management and regenerative solutions, and its products are delivered in key sites of care, including ambulatory surgery centers. Its products include OA Pain Management, Regenerative Solutions, and others. The OA Pain Management product family consists of Cingal, Monovisc, Orthovisc, Orthovisc mini and Orthovisc-T. Its Regenerative Solutions include Integrity, Hyalofast, Tactoset and NanoFx. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Anika Therapeutics Inc is a good buy right now due to its recent performance and positive outlook. The current price is $21.10, which is below the analyst price target of $21, indicating potential upside. The company reported a 17% year-over-year revenue growth in Q2, with a gross margin of 65.15%, suggesting improving profitability. However, the main risk is the negative net income of $5.06 million in Q1 2026, which could impact future performance.

3 analysts cover ANIK: 2 rate it Buy, 1 Hold and 0 Sell. The average price target is 16.00.